Cypress Capital Management (Delaware)’s AbbVie ABBV Stock Holding History

Cypress Capital Management (Delaware)’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,701	Closed	-$228K	–	3
2022 Q3	$228K	Hold	1,701	–	–	0.04%	188
2022 Q2	$261K	Hold	1,701	–	–	0.04%	176
2022 Q1	$276K	Sell	1,701 -800	-32%	-$116K	0.03%	183
2021 Q4	$339K	Sell	2,501 -194	-7%	-$22.9K	0.04%	175
2021 Q3	$304K	Hold	2,695	–	–	0.04%	157
2021 Q2	$304K	Buy	2,695 +200	+8%	+$22.5K	0.04%	157
2021 Q1	$270K	Buy	2,495 +44	+2%	+$4.71K	0.04%	157
2020 Q4	$263K	Buy	+2,451	New	+$236K	0.04%	158

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cypress Capital Management (Delaware)'s ABBV Position: Q4 2022 in Review

Cypress Capital Management (Delaware) sold out of AbbVie (ABBV) in Q4 2022, closing a stake of 1,701 shares — an estimated $228K sold.

Cypress Capital Management (Delaware) first reported a position in ABBV in Q4 2020 and held it in 8 quarters. The position peaked at $339K in Q4 2021. 3,171 funds tracked by Wall St. Rank hold ABBV as of Q4 2022.

Cypress Capital Management (Delaware) reported no remaining AbbVie position as of Q4 2022 after selling out during the quarter.
Cypress Capital Management (Delaware) sold 1,701 AbbVie shares in Q4 2022, an estimated $228K.
Cypress Capital Management (Delaware) first reported a position in AbbVie in Q4 2020 and held it in 8 quarters.
Cypress Capital Management (Delaware)'s AbbVie position peaked at $339K in Q4 2021.
3,171 funds tracked by Wall St. Rank held AbbVie as of Q4 2022.

Based on Cypress Capital Management (Delaware)'s 13F filing for Q4 2022.